Cargando…
MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary
Metastasis is responsible for the majority of cancer‐related deaths. Particularly, challenging is the management of metastatic cancer of unknown primary site (CUP), whose tissue of origin (TOO) remains undetermined even after extensive investigations and whose therapy is rather unspecific and poorly...
Autores principales: | Laprovitera, Noemi, Riefolo, Mattia, Porcellini, Elisa, Durante, Giorgio, Garajova, Ingrid, Vasuri, Francesco, Aigelsreiter, Ariane, Dandachi, Nadia, Benvenuto, Giuseppe, Agostinis, Federico, Sabbioni, Silvia, Berindan Neagoe, Ioana, Romualdi, Chiara, Ardizzoni, Andrea, Trerè, Davide, Pichler, Martin, D'Errico, Antonietta, Ferracin, Manuela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486570/ https://www.ncbi.nlm.nih.gov/pubmed/34075699 http://dx.doi.org/10.1002/1878-0261.13026 |
Ejemplares similares
-
Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches
por: Laprovitera, Noemi, et al.
Publicado: (2021) -
Cancer of Unknown Primary: Challenges and Progress in Clinical Management
por: Laprovitera, Noemi, et al.
Publicado: (2021) -
Cancer Site-Specific Multiple microRNA Quantification by Droplet Digital PCR
por: Laprovitera, Noemi, et al.
Publicado: (2018) -
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
por: Sisi, Monia, et al.
Publicado: (2023) -
KRAS and ERBB-family genetic alterations affect response to PD-1
inhibitors in metastatic nonsquamous NSCLC
por: Cinausero, Marika, et al.
Publicado: (2019)